pFRT/lacZeo Vector
Product Image
Invitrogen™

pFRT/lacZeo Vector

pFRT/lacZeoおよびpFRT/lacZeo2は、単一のFRT部位を含むFlp-In Cell™ Linesを確立するために構築されています。各ベクターには以下が含まれます。•その後のFlp-in発現ベクターのターゲット統合のためのFRT部位™ゼオシン™での安定した統合のために選択されたZ-ゼオシン™融合 これらのベクターは、lacZ-ゼオシン™融合タンパク質の発現を促進するSv40プロモーターでは異なります。pFRT/lacZeo2には、SV40プロモーターの省略されたバージョンが含まれます詳細を見る
製品番号(カタログ番号)数量
V60152020 μg
製品番号(カタログ番号) V601520
価格(JPY)
65,000
Online offer
Ends: 27-Mar-2026
92,900
割引額 27,900 (30%)
20 µg
お問い合わせください ›
数量:
20 μg
pFRT/lacZeoおよびpFRT/lacZeo2は、単一のFRT部位を含むFlp-In Cell™ Linesを確立するために構築されています。各ベクターには以下が含まれます。

•その後のFlp-in発現ベクターのターゲット統合のためのFRT部位™
ゼオシン™での安定した統合のために選択されたZ-ゼオシン™融合

これらのベクターは、lacZ-ゼオシン™融合タンパク質の発現を促進するSv40プロモーターでは異なります。pFRT/lacZeo2には、SV40プロモーターの省略されたバージョンが含まれます。このベクターを使用すると、ゲノムのエンハンサー要素に近いベクターを統合したクローンの単離が容易になります。pFRT/lacZeo2を使用して安定クローンを選択すると、目的の遺伝子をより高いレベルで発現するクローンの単離が容易になります。
研究用にのみ使用できます。診断用には使用いただけません。
仕様
構成または誘導システム構造的
供給タイプTransfection
使用対象(アプリケーション)ターゲット統合
製品タイプFlp-Inシステム発現ベクター
数量20 μg
レポーター遺伝子β-gal(lacZ)
選択剤(真核生物)ゼオシン™
ベクターpFRT
製品ラインFlp-In
プロモーターSV40
タンパク質タグタグなし
Unit Size20 µg
組成および保存条件
20 µgのベクター、pFRT/lacZeoまたはpFRT/lacZeo2が超らせん型で凍結乾燥されて提供されます。再懸濁後、-20℃で保管してください。ベクターは、適切に保存されている場合、6ケ月間安定していることが保証されます。

よくあるご質問(FAQ)

Do I need to include a consensus Kozak sequence when I clone my gene of interest into one of your mammalian expression vectors?

The consensus Kozak sequence is A/G NNATGG, where the ATG indicates the initiation codon. Point mutations in the nucleotides surrounding the ATG have been shown to modulate translation efficiency. Although we make a general recommendation to include a Kozak consensus sequence, the necessity depends on the gene of interest and often, the ATG alone may be sufficient for efficient translation initiation. The best advice is to keep the native start site found in the cDNA unless one knows that it is not functionally ideal. If concerned about expression, it is advisable to test two constructs, one with the native start site and the other with a consensus Kozak. In general, all expression vectors that have an N-terminal fusion will already have an initiation site for translation.

Find additional tips, troubleshooting help, and resources within our Protein Expression Support Center.

Do I need to include a ribosomal binding site (RBS/Shine Dalgarno sequence) or Kozak sequence when I clone my gene of interest?

ATG is often sufficient for efficient translation initiation although it depends upon the gene of interest. The best advice is to keep the native start site found in the cDNA unless one knows that it is not functionally ideal. If concerned about expression, it is advisable to test two constructs, one with the native start site and the other with a Shine Dalgarno sequence/RBS or consensus Kozak sequence (ACCAUGG), as the case may be. In general, all expression vectors that have an N-terminal fusion will already have a RBS or initiation site for translation.

Find additional tips, troubleshooting help, and resources within our Protein Expression Support Center.

Can you tell me the difference between a Shine-Dalgarno sequence and a Kozak sequence?

Prokaryotic mRNAs contain a Shine-Dalgarno sequence, also known as a ribosome binding site (RBS), which is composed of the polypurine sequence AGGAGG located just 5’ of the AUG initiation codon. This sequence allows the message to bind efficiently to the ribosome due to its complementarity with the 3’-end of the 16S rRNA. Similarly, eukaryotic (and specifically mammalian) mRNA also contains sequence information important for efficient translation. However, this sequence, termed a Kozak sequence, is not a true ribosome binding site, but rather a translation initiation enhancer. The Kozak consensus sequence is ACCAUGG, where AUG is the initiation codon. A purine (A/G) in position -3 has a dominant effect; with a pyrimidine (C/T) in position -3, translation becomes more sensitive to changes in positions -1, -2, and +4. Expression levels can be reduced up to 95% when the -3 position is changed from a purine to pyrimidine. The +4 position has less influence on expression levels where approximately 50% reduction is seen. See the following references:

- Kozak, M. (1986) Point mutations define a sequence flanking the AUG initiator codon that modulates translation by eukaryotic ribosomes. Cell 44, 283-292.
- Kozak, M. (1987) At least six nucleotides preceding the AUG initiator codon enhance translation in mammalian cells. J. Mol. Biol. 196, 947-950.
- Kozak, M. (1987) An analysis of 5´-noncoding sequences from 699 vertebrate messenger RNAs. Nucleic Acids Res. 15, 8125-8148.
- Kozak, M. (1989) The scanning model for translation: An update. J. Cell Biol. 108, 229-241.
- Kozak, M. (1990) Evaluation of the fidelity of initiation of translation in reticulocyte lysates from commercial sources. Nucleic Acids Res. 18, 2828.

Note: The optimal Kozak sequence for Drosophila differs slightly, and yeast do not follow this rule at all. See the following references:

- Romanos, M.A., Scorer, C.A., Clare, J.J. (1992) Foreign gene expression in yeast: a review. Yeast 8, 423-488.
- Cavaneer, D.R. (1987) Comparison of the consensus sequence flanking translational start sites in Drosophila and vertebrates. Nucleic Acids Res. 15, 1353-1361.

Find additional tips, troubleshooting help, and resources within our Protein Expression Support Center.

I sequenced one of your vectors after PCR amplification and observed a difference from what is provided online (or in the manual). Should I be concerned?

Our vectors have not been completely sequenced. Your sequence data may differ when compared to what is provided. Known mutations that do not affect the function of the vector are annotated in public databases.

Are your vectors routinely sequenced?

No, our vectors are not routinely sequenced. Quality control and release criteria utilize other methods.